Pyrimidine derivatives, their preparation and use
Novel pyrimidine derivatives provide effective inhibition of CDK2, CDK4, and CDK6, addressing the need for targeted CDK inhibitors in cancer and other disorders, with improved efficacy over existing treatments.
Patent Information
- Application Number
- JP2022579075
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-07-03
- Filing Date
- 2021-07-02
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-07-02
AI Technical Summary
Current treatments for cancer and other cell proliferation disorders lack effective inhibitors targeting cyclin-dependent kinases (CDKs), particularly CDK2, despite the known role of these kinases in tumor formation and progression.
Development of pyrimidine derivatives with novel structures that selectively inhibit CDK2, CDK4, and CDK6, offering a new class of CDK inhibitors.
The pyrimidine derivatives demonstrate potent CDK inhibitory effects, particularly against CDK2, CDK4, and CDK6, with IC50 values lower than Abemaciclib, showing promise in treating various cancers and other disorders.
Smart Images

Figure 0007583838000001 
Figure 0007583838000002 
Figure 0007583838000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to a Chinese patent application bearing application number 202010629992.X and entitled "Pyrimidine Derivatives and Their Preparation and Use," filed with the State Intellectual Property Office of the People's Republic of China on July 3, 2020, which is incorporated herein by reference in its entirety.
[0002] This application relates to compounds, more particularly to pyrimidine derivatives and their preparation and use. [Background technology]
[0003] Tumors are associated with cell cycle abnormalities, and most tumor cells have many mutations in mitotic signaling proteins, defects in antimitotic signaling proteins, and genomic instability (GIN) and chromosomal instability (CIN). Many studies have found that these three basic cell cycle defects are directly or indirectly caused by loss of control of cyclin-dependent kinases (CDKs). CDKs exert their roles by binding to their regulatory subunits, cyclins, and four major classes of cyclins (A-, B-, D-, and E-type cyclins) exert different roles in different phases of the cell cycle, and at least 16 mammalian cyclins have been identified. The cyclins Cyclin B / CDK1, Cyclin A / CDK2, Cyclin E / CDK2, Cyclin D / CDK4, Cyclin D / CDK6, Cyclin T1 / CDK9 and other heterodimers (including CDK3 and CDK7) are important regulators of cell cycle progression. Other functions of cyclin / CDK heterodimers include regulation of transcription, DNA repair, differentiation and programmed cell death (Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. (1997) 13:261-291).
[0004] Related studies have shown that increased activity or abnormal activation of cyclin-dependent kinases leads to the formation of human tumors. In fact, the formation of human tumors is generally related to the variation of CDK proteins themselves or their regulators. CDK4 and CDK6 are highly homologous, and it was found that CDK4 single gene knockout mice have diabetic symptoms and cell defects, CDK6 single gene knockout mice have mild anemia symptoms due to defective proliferation of hematopoietic cells, and CDK4 and CDK6 (CDK4 / 6) double gene knockout mice have late embryonic death due to impaired proliferation ability of hematopoietic progenitor cells. Hyperactivation of the CDK4 / 6-Cyclin D / Rb (phosphorylated retinoblastoma gene) signaling pathway is commonly found in tumor cells. Stimulated by various intracellular and extracellular mitogenic signals, Cyclin D is highly expressed, which regulates the interaction of CDK4 / 6 proteins with Cyclin D and promotes the localization and kinase activity of CDK4 / 6. Activated CDK4 / 6 phosphorylates Rb, dissociating the Rb-E2F complex and releasing free E2F into the nucleus to regulate protein transcription and initiate cell cycle progression. Hyperactivation of CDK4 is commonly found in epithelial cell malignancies, while hyperactivation of CDK6 is commonly found in mesenchymal cell tumors such as sarcomas and hematological cancers. In an experiment using a breast cancer-bearing mouse model, tumors were formed in all wild-type nude mice, but no tumors were formed in CDK4 knockout nude mice. It was found that blocking the expression of CDK4 with anti-CDK4 siRNA significantly inhibited tumor growth in nude mice.
[0005] In vitro experiments have found that naturally occurring CDK protein inhibitors, such as p16 and p27, can inhibit the proliferation of lung cancer cell lines. Studies have also found that cyclin E (a regulatory cyclin of CDK2) is always overexpressed in cancer. It has been recognized that amplification or overexpression of cyclin E is associated with poor prognosis in breast cancer (Keyomarsi et al., Cyclin E and survival in patients with breast cancer. N Engl J Med. (2002) 347: 1566-75). Overexpression of cyclin E2 (CCNE2) is associated with endocrine resistance in breast cancer cells, and related reports have shown that inhibition of CDK2 can restore tamoxifen resistance and sensitivity to tamoxifen or CDK4 inhibitors in CCNE2-overexpressing cells (Caldon et al.,Cyclin E2 overexpression is associated with endocrine resistance but not in sensitivity to CDK2 inhibition in human breast cancer cells.Mol Cancer Ther.(2012)11:1488-99;Herrera-Abreu et al.,Early Adaptation and Acquired Resistance to CDK4 / 6 Inhibition in Estrogen Receptor-Positive Breast Cancer,Cancer Res.(2016)76:2301-2313). According to a related report, cyclin E amplification / overexpression contributes to resistance to trastuzumab in HER2+ breast cancer (Scaltriti et al.,Cyclin E amplification / overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients,Proc Natl Acad Sci.(2011) 108: 3761-6). In addition, according to related reports, overexpression of cyclin E also plays a role in basal-like breast cancer, triple-negative breast cancer (TNBC) and inflammatory breast cancer (Elsawaf & Sinn, Triple Negative Breast Cancer: Clinical and Histological Correlations, Breast Care (2011) 6: 273-278 Alexander et al., Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer, Oncotarget (2017) 8: 14897-14911). Amplification or overexpression of Cyclin E1 (CCNE1) has also been associated with poor prognosis in ovarian, gastric, endometrial and other cancers (Nakayama et al., Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer, Cancer (2010) 116: 2621-34; Etemadmoghadam et al., Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer, Clin Cancer Res (2013) 19: 5960-71; Au-Yeung et al., Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition, Clin. Cancer Res. (2017) 23: 1862-1874; Ayhan et al.,CCNE1 copynumber gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis,Modern Pathology(2017)30:297-303;Ooi et al.,Gene amplification of CCNE1,CCND1,and CDK6 in gastric cancers detected bymultiplex ligation-dependent probe amplification and fluorescence in situ hybridization,Hum Pathol.(2017)61:58-67;Noske et al.,Detection of CCNE1 / URI(19q12)amplification by in situ hybridisation is common in high grade and type II endometrial cancer,Oncotarget(2017)8:14794-14805). Dinaciclib (MK-7965), a small molecule inhibitor used to block CDK1, CDK2, CDK5 and CDK9, is currently in clinical development for breast and hematological cancers. Seliciclib (roscovitine or CYC202), an inhibitor of CDK2, CDK7, and CDK9, is also being used to treat advanced solid tumors in combination with chemotherapy.
[0006] Besides inhibiting tumor growth, CDK inhibitors are also used to treat cardiovascular disorders (e.g., restenosis, atherosclerosis, and other vascular disorders caused by abnormal cell proliferation), diseases caused by various infectious agents (e.g., fungi, protozoan parasites (e.g., Plasmodium falciparum), DNA and RNA viruses), and various autoimmune diseases. In a rat model of arthritis, joint swelling was largely suppressed by p16-expressing adenovirus, and studies have shown that CDK inhibitors are also effective in other cell proliferation disorders (e.g., psoriasis, glomerulonephritis, and lupus, which are characterized by hyperproliferation of keratinocytes).
[0007] In addition, research has also found that cells transitioning from G1 to S phase and from G2 to M phase of the cell cycle are extremely sensitive to DNA damaging factors (e.g., ionizing radiation (IR)), and that at least three cyclin-dependent kinases (CDK2, CDK4, CDK6) and their regulatory subunits, cyclins, must cooperate to phosphorylate and regulate Rb family proteins during the transition from G1 to S phase. Selective CDK4 / 6 inhibitors can induce cell G1 arrest, enhance the resistance of hematopoietic stem / progenitor cells to DNA damaging factors (e.g., IR), and effectively alleviate various blood toxicities caused by radiation (e.g., bone marrow suppression, neutropenia, leukopenia, anemia, etc.).
[0008] Studies have also found that overexpression of CDK2 is associated with abnormal regulation of the cell cycle. The cyclin E / CDK2 complex plays an important role in regulating the transition from G1 to S phase, histone biosynthesis, and centrosome duplication. Cyclin D / CDK4 / 6 and cyclin E / CDK2 release the G1 transcription factor E2F upon the progressive phosphorylation of Rb, promoting the transition to S phase. Activation of cyclin A / CDK2 early in S phase promotes phosphorylation of endogenous substrates, allowing DNA replication and inactivation of E2F, thus completing the S phase (Asghar et al.,The history and future of targeting cyclin-dependent kinasesin cancer therapy,Nat.Rev.Drug.Discov.2015;14(2):130-146).
[0009] Patent applications disclosing inhibitors that selectively inhibit CDK4 and CDK6 include WO2003062236, WO2006008874, WO2009126584, etc. Despite enormous efforts, no drugs targeting CDK2 have been approved, so there is a need to find CDK inhibitors with new activity profiles, especially those that target CDK2.
[0010] The contents disclosed in the Background section are intended to enhance the overall understanding of the background of the present application, and should not be construed as an admission or in any way suggesting that the contents constitute prior art known to those skilled in the art. Summary of the Invention [Problem to be solved by the invention]
[0011] The present application aims to provide a pyrimidine derivative having a novel structure, and a method for producing and using the same, which exhibits excellent CDK inhibitory effects and functions. [Means for solving the problem]
[0012] The present application has been made to achieve the above-mentioned object, and provides a pyrimidine derivative selected from a compound represented by general formula (I) or a tautomer, enantiomer, diastereomer, mesomeric, racemic form, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof: [ka] In the formula, R1 and R2 are each independently selected from fluorine or chlorine; R3 is selected from hydrogen, fluorine, or a hydroxy group; A is selected from a methylene group or a covalent bond; Q is selected from carbon and nitrogen atoms, provided that When Q is a carbon atom, X is -NR4R6; When Q is a nitrogen atom and R is hydrogen, X is -R; When Q is a nitrogen atom and R3 is a fluorine or hydroxy group, X is a C1-C3 alkyl group, a C3-C7 cycloalkyl group, or R5; R4 is selected from hydrogen or a C1-C3 alkyl group; R5 is, [ka] R, R' and R" are each independently selected from hydrogen and a C1-C3 alkyl group; R6 is a C1 to C3 alkyl group, a C3 to C7 cycloalkyl group, or R5.
[0013] In one possible embodiment, in the compounds of general formula (I), when Q is a nitrogen atom and R3 is hydrogen, R, R' and R" in R5 are independently selected from hydrogen and methyl groups.
[0014] In one possible embodiment, in the compound represented by general formula (I), when Q is a nitrogen atom and R3 is a fluorine or a hydroxy group, X is an ethyl group or R5, in which R, R' and R" are independently selected from hydrogen and a methyl group.
[0015] In one possible embodiment, in the compounds of general formula (I), when Q is a carbon atom, R4 is hydrogen or a methyl group, R6 is a methyl group, an ethyl group or R5, in which R, R' and R" are independently selected from hydrogen and a methyl group.
[0016] In one possible embodiment, in the compound represented by general formula (I), R1 and R2 are both fluorine, R3 is hydrogen, A is selected from a methylene group or a covalent bond, Q is a nitrogen atom, and R, R' and R" in R5 are each independently selected from a hydrogen or a methyl group.
[0017] In one possible embodiment, in the compound represented by general formula (I), R1 and R2 are both fluorine, R3 is fluorine, A is selected from a methylene group or a covalent bond, Q is a nitrogen atom and X is an ethyl group.
[0018] In one possible embodiment, in the compound represented by general formula (I), R1 and R2 are both fluorine, R3 is hydrogen or fluorine, A is selected from a methylene group and a covalent bond, Q is a carbon atom, R4 is hydrogen or a methyl group, and R6 is a methyl group, an ethyl group or a hydroxyethyl group.
[0019] In one possible embodiment, the compound of general formula (I) is chosen from the compounds having the following structure: [ka] [ka] [ka]
[0020] The present application further provides a method for preparing a pyrimidine derivative, the method being selected from the following methods: (1) The existing compounds IA and IB are cyclized to generate benzimidazole IC, which is then converted into a boronic acid pinacol ester and reacted with ID via Suzuki coupling to generate IE, and finally IE is reacted with the corresponding 2-aminopyridine via Buchwald-Hartwig coupling reaction to generate the representative structure I. [ka] (2) [ka] (3) [ka] In the formula, R1, R2, R3, A, Q, and X are the same as the corresponding groups of the pyrimidine derivative, and Y is a halogen element.
[0021] The present application further provides the use of said pyrimidine derivatives as active ingredients in the manufacture of a pharmaceutical composition.
[0022] In one possible embodiment, the pharmaceutical composition is a drug for treating a cell proliferation disorder, an infectious disease (e.g., a viral infection (e.g., herpes, HIV), a fungal infection, etc.), an inflammatory disease (e.g., rheumatoid arthritis, osteoarthritis, etc.), an autoimmune disease (e.g., psoriasis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, glomerulonephritis, etc.), a cardiovascular disease (e.g., myocardial infarction, stroke, atherosclerosis, postoperative vascular stenosis, restenosis, etc.), or a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, etc.), or a blood toxicity disease caused by radiation (e.g., myelosuppression, neutropenia, leukopenia, anemia).
[0023] In one possible embodiment, treating the cell proliferative disorder is treating cancer, and optionally, the cancer is selected from the group consisting of breast cancer, ovarian cancer, prostate cancer, melanoma, brain tumors (e.g., gliomas with malignant astrocytoma and oligodendroglioma components), esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer (e.g., colon cancer, rectal cancer), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, primary or metastatic squamous cell carcinoma, etc.), renal cancer, skin cancer, glioblastoma, neuroblastoma, sarcoma, liposarcoma, osteochondroma, osteoma, osteosarcoma, seminoma, testicular tumor, uterine cancer (e.g., cervical cancer, endometrial cancer, and the like), head and neck tumors (e.g., maxilla cancer, laryngeal cancer, pharyngeal cancer, tongue cancer, oral cavity cancer, and the like), multiple myeloma, malignant lymphoma (e.g., reticulum cell sarcoma, lymphosarcoma, Hodgkin's lymphoma, mantle cell lymphoma, and the like), polycythemia vera, leukemia (e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and the like), thyroid tumor, ureter tumor, bladder tumor, gallbladder cancer, bile duct cancer, chorioepithelioma, or childhood cancer, and the like (e.g., Ewing's sarcoma family of tumors, Wilms' tumor, rhabdomyosarcoma, angiosarcoma, embryonal testicular tumor, neuroblastoma, retinoblastoma, hepatoblastoma, nephroblastoma, and the like).
[0024] In one possible embodiment, the cancer is breast cancer or ovarian cancer.
[0025] The present application further provides pharmaceutical compositions comprising said pyrimidine derivatives as an active ingredient, and further comprising one or more pharma- ceutically acceptable carriers, diluents or excipients.
[0026] In one possible embodiment, the pharmaceutical composition further comprises one or more other anti-cancer drugs as active ingredients, the anti-cancer drugs being alkylating agents (e.g., cyclophosphamide, ifosfamide, melphalan, busulfan, nimustine, ranimustine, dacarbazine, temozolomide, nitrogen mustard, dibromomannitol, etc.), platinum complexes (e.g., cisplatin, carboplatin, oxaliplatin, etc.), antimetabolites (e.g., methotrexate, , 5-fluorouracil, tegafur, gemcitabine, capecitabine, fulvestrant, pemetrexed, etc.), plant-derived alkaloids (e.g., vincristine, vinblastine, vindesine, etoposide, docetaxel, paclitaxel, irinotecan, vinorelbine, mitoxantrone, vinflunine, topotecan, etc.), antibody drugs (e.g., trastuzumab, pertuzumab, rituximab, cetuximab, panitumumab, bevacizumab, etc.) etc.), antitumor hormone drugs (e.g., leuprorelin, goserelin, dutasteride, dexamethasone, tamoxifen, etc.), proteasome inhibitors (e.g., bortezomib, lenalidomide, etc.), aromatase inhibitors (e.g., exemestane, letrozole, anastrozole, etc.), VEGFR or EGFR inhibitors (e.g., sunitinib, sorafenib, imatinib, gefitinib, erlotinib, vandetanib, pazopanib, lapatinib, nib, etc.), mTOR inhibitors (e.g., everolimus, sirolimus, zotarolimus, etc.), PI3K kinase inhibitors (e.g., BKM-120, XL-147, BEZ-235, etc.), B-Raf inhibitors (e.g., vemurafenib, GSK-2118436, etc.), or AKT inhibitors (e.g., perifosine, MK-2206, etc.), preferably an aromatase inhibitor, more preferably letrozole or anastrozole.
[0027] The present application further provides a method for treating a disease, comprising administering an effective amount of the pyrimidine derivative to a subject in need of the treatment, the disease being a cell proliferation disorder, an infectious disease (e.g., a viral infection (e.g., herpes, HIV), a fungal infection, etc.), an inflammatory disease (e.g., rheumatoid arthritis, osteoarthritis, etc.), an autoimmune disease (e.g., psoriasis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, glomerulonephritis, etc.), a cardiovascular disease (e.g., myocardial infarction, stroke, atherosclerosis, postoperative vascular stenosis, restenosis, etc.), or a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, etc.), or a blood toxicity disease caused by radiation (e.g., bone marrow suppression, neutropenia, leukopenia, anemia).
[0028] In one possible embodiment, the abnormal cell proliferative disorder is cancer, and optionally the cancer is selected from the group consisting of breast cancer, ovarian cancer, prostate cancer, melanoma, brain tumors (e.g., gliomas, including astrocytomas and oligodendrogliomas), esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer (e.g., colon cancer, rectal cancer), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, primary or metastatic squamous cell carcinoma, etc.), renal cancer, skin cancer, glioblastoma, neuroblastoma, sarcoma, liposarcoma, osteochondroma, osteoma, osteosarcoma, seminoma, testicular tumor, uterine cancer (e.g., cervical cancer, endometrial cancer, etc.), head and neck tumors. (e.g., maxilla cancer, laryngeal cancer, pharyngeal cancer, tongue cancer, oral cavity cancer, etc.), multiple myeloma, malignant lymphoma (e.g., reticulum cell sarcoma, lymphosarcoma, Hodgkin's lymphoma, mantle cell lymphoma, etc.), polycythemia vera, leukemia (e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, etc.), thyroid tumor, ureter tumor, bladder tumor, gallbladder cancer, bile duct cancer, chorioepithelioma, or childhood cancer (e.g., Ewing's sarcoma family of tumors, Wilms' tumor, rhabdomyosarcoma, angiosarcoma, embryonal testicular tumor, neuroblastoma, retinoblastoma, hepatoblastoma, nephroblastoma, etc.).
[0029] In one possible embodiment, the cancer is breast cancer or ovarian cancer.
[0030] In one possible embodiment, the breast cancer is triple-negative breast cancer.
[0031] In one possible embodiment, the method further comprises administering one or more additional anti-cancer drugs as active ingredients, the anti-cancer drugs being alkylating agents (e.g., cyclophosphamide, ifosfamide, melphalan, busulfan, nimustine, ranimustine, dacarbazine, temozolomide, nitrogen mustard, dibromomannitol, etc.), platinum complexes (e.g., cisplatin, carboplatin, oxaliplatin, etc.), antimetabolites (e.g., , methotrexate, 5-fluorouracil, tegafur, gemcitabine, capecitabine, fulvestrant, pemetrexed, etc.), plant-derived alkaloids (e.g., vincristine, vinblastine, vindesine, etoposide, docetaxel, paclitaxel, irinotecan, vinorelbine, mitoxantrone, vinflunine, topotecan, etc.), antibody drugs (e.g., trastuzumab, pertuzumab, rituximab, cetuximab, panitumumab, bevacizumab, etc.), antitumor hormone drugs (e.g., leuprorelin, goserelin, dutasteride, dexamethasone, tamoxifen, etc.), proteasome inhibitors (e.g., bortezomib, lenalidomide, etc.), aromatase inhibitors (e.g., exemestane, letrozole, anastrozole, etc.), VEGFR or EGFR inhibitors (e.g., sunitinib, sorafenib, The inhibitor is selected from among rifametinib, imatinib, gefitinib, erlotinib, vandetanib, pazopanib, lapatinib, etc.), mTOR inhibitors (e.g., everolimus, sirolimus, zotarolimus, etc.), PI3K kinase inhibitors (e.g., BKM-120, XL-147, BEZ-235, etc.), B-Raf inhibitors (e.g., vemurafenib, GSK-2118436, etc.), or AKT inhibitors (e.g., perifosine, MK-2206, etc.). Preferably, it is an aromatase inhibitor, more preferably letrozole or anastrozole.
[0032] The present application further provides a CDK inhibitor comprising the pyrimidine derivative.
[0033] In one possible embodiment, the CDKs include CDK2, CDK4, CDK6.
[0034] The present application further provides a method for producing the CDK inhibitor, comprising the step of producing the pyrimidine derivative according to any one of claims 1 to 4 using the production method.
[0035] The present application further provides the use of said CDK inhibitor as an active ingredient in the manufacture of a pharmaceutical composition.
[0036] In one possible embodiment, the pharmaceutical composition is a drug for treating a cell proliferation disorder, an infectious disease (e.g., a viral infection (e.g., herpes, HIV), a fungal infection, etc.), an inflammatory disease (e.g., rheumatoid arthritis, osteoarthritis, etc.), an autoimmune disease (e.g., psoriasis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, glomerulonephritis, etc.), a cardiovascular disease (e.g., myocardial infarction, stroke, atherosclerosis, postoperative vascular stenosis, restenosis, etc.), a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, etc.), or a blood toxicity disease caused by radiation (e.g., bone marrow suppression, neutropenia, leukopenia, anemia).
[0037] In one possible embodiment, treating said cell proliferative disorder is treating cancer.
[0038] In one possible embodiment, the cancer is breast cancer, ovarian cancer, prostate cancer, melanoma, brain tumors (e.g., gliomas with malignant astrocytoma and oligodendroglioma components, etc.), esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer (e.g., colon cancer, rectal cancer, etc.), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, primary or metastatic squamous cell carcinoma, etc.), renal cancer, skin cancer, glioblastoma, neuroblastoma, sarcoma, liposarcoma, osteochondroma, osteoma, osteosarcoma, seminoma, testicular tumor, uterine cancer (e.g., cervical cancer, endometrial cancer, etc.), head and neck tumors (e.g., maxillary cancer, laryngeal cancer, pharyngeal cancer, tongue cancer, oral cancer, etc.), multiple myeloma, malignant lymphoma (e.g., reticulum cell sarcoma, lymphosarcoma, Hodgkin's lymphoma, mantle cell lymphoma, etc.), polycythemia vera, leukemia (e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, etc.), thyroid tumor, ureter tumor, bladder tumor, gallbladder cancer, bile duct cancer, chorioepithelioma, or childhood cancer (e.g., Ewing's sarcoma family of tumors, Wilms' tumor, rhabdomyosarcoma, angiosarcoma, embryonal testicular tumor, neuroblastoma, retinoblastoma, hepatoblastoma, nephroblastoma, etc.).
[0039] In one possible embodiment, the cancer is breast cancer or ovarian cancer.
[0040] In one possible embodiment, the breast cancer is triple-negative breast cancer.
[0041] The pharmaceutical composition comprises the CDK inhibitor as an active ingredient, and further comprises one or more pharma- ceutically acceptable carriers, diluents or excipients.
[0042] In one possible embodiment, the pharmaceutical composition further comprises one or more other anti-cancer drugs as active ingredients, the anti-cancer drugs being alkylating agents (e.g., cyclophosphamide, ifosfamide, melphalan, busulfan, nimustine, ranimustine, dacarbazine, temozolomide, nitrogen mustard, dibromomannitol, etc.), platinum complexes (e.g., cisplatin, carboplatin, oxaliplatin, etc.), antimetabolites (e.g., methotrexate, 5-fluorouracil, etc.), fluorouracil, tegafur, gemcitabine, capecitabine, fulvestrant, pemetrexed, etc.), plant-derived alkaloids (e.g., vincristine, vinblastine, vindesine, etoposide, docetaxel, paclitaxel, irinotecan, vinorelbine, mitoxantrone, vinflunine, topotecan, etc.), antibody drugs (e.g., trastuzumab, pertuzumab, rituximab, cetuximab, panitumumab, bevacizumab, etc.), antitumor hormones Monocyte drugs (e.g., leuprorelin, goserelin, dutasteride, dexamethasone, tamoxifen, etc.), proteasome inhibitors (e.g., bortezomib, lenalidomide, etc.), aromatase inhibitors (e.g., exemestane, letrozole, anastrozole, etc.), VEGFR or EGFR inhibitors (e.g., sunitinib, sorafenib, imatinib, gefitinib, erlotinib, vandetanib, pazopanib, lapatinib, etc.), mTOR inhibitors (e.g., everolimus, sirolimus, zotarolimus, etc.), PI3K kinase inhibitors (e.g., BKM-120, XL-147, BEZ-235, etc.), B-Raf inhibitors (e.g., vemurafenib, GSK-2118436, etc.), or AKT inhibitors (e.g., perifosine, MK-2206, etc.), and the other one or more anticancer agents are preferably aromatase inhibitors, and more preferably letrozole or anastrozole.
[0043] The present application further provides a method for inhibiting CDK activity, comprising the step of administering to a subject in need of inhibition of CDK activity an effective amount of the pyrimidine derivative. Effect of the Invention
[0044] The pyrimidine derivatives of the present application show excellent CDK inhibitory effects and functions, particularly inhibiting CDK2, CDK4, and CDK6. They have a lower IC 50 The values are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] In the following, in order to make the objectives, technical solutions and advantages of the present application clearer, the technical solutions of the present application are described clearly and completely using examples. Needless to say, the described examples are only some of the embodiments of the present application, but are not all of the embodiments. If a person skilled in the art obtains other embodiments based on the embodiments of the present application without performing any novel work, they all fall within the protection scope of the present application.
[0046] In addition, in order to further explain the present application, many details are shown in the following embodiments. Those skilled in the art can understand that the present application can be similarly implemented even without some details. In some examples, materials, components, methods, means, etc. known to those skilled in the art are not described in detail in order to enhance the gist of the present application.
[0047] Unless otherwise stated, throughout the specification and claims, the term "comprise" or its equivalents (e.g., "contains" or "containing") are to be understood as including the recited element or components but not excluding other elements or components.
[0048] The term "alkyl group" refers to saturated aliphatic hydrocarbon groups, including straight and branched chain groups, of 1 to 20 carbon atoms. Preferred are alkyl groups containing 1 to 10 carbon atoms, more preferably alkyl groups containing 1 to 6 carbon atoms, and most preferably alkyl groups containing 1 to 4 carbon atoms, with methyl being the most preferred of these. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 6-methylhexyl, 7-methylhexyl, 8-methylhexyl, 9-methylhexyl, 10-methylhexyl, 11-methylhexyl, 12-methylhexyl, 13-methylhexyl, 14-methylhexyl, 15-methylhexyl, 16-methylhexyl, 17-methylhexyl, 18-methylhexyl, 19-methylhexyl, 22-methylhexyl, 23-methylhexyl, 24-methylhexyl, 25-methylhexyl, 26-methylhexyl, 27-methylhexyl, 28-methylhexyl, 29-methylhexyl, 30-methylhexyl, 31-methylhexyl, 32-methylhexyl, 33-methylhexyl, 34-methylhexyl, 35-methylhexyl, 36-methylhexyl, 37-methylhexyl, 38-methylhexyl, 39-methylhexyl, 40-methylhexyl, 41-methylhexyl, 42-methylhexyl, 43-methylhexyl, 44-methylhexyl, 45-methylhex Examples of such groups include 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof.More preferred are lower alkyl groups containing from 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available attachment site, and the substituent is preferably one or more independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxy groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, oxo groups, amino groups, haloalkyl groups, hydroxyalkyl groups, carboxy groups, and carboxylate groups.
[0049] The term "cycloalkyl group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the ring of the cycloalkyl group contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, most preferably 3 to 6 carbon atoms, most preferably cyclopropyl or cyclopentyl. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc., preferably cyclopropyl and cyclopentyl. Polycyclic cycloalkyl groups include spiro, fused or bridged cycloalkyl groups. The cycloalkyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxy groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, oxo groups, amino groups, haloalkyl groups, hydroxyalkyl groups, carboxy groups, and carboxylate groups.
[0050] The term "alkoxy group" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl) groups, where alkyl and cycloalkyl groups are as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like. The alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxy, and carboxylic acid ester groups.
[0051] "Haloalkyl group" refers to an alkyl group substituted with one or more halogens, where alkyl group is as defined above.
[0052] "Hydroxy" refers to an -OH group.
[0053] "Hydroxyalkyl group" refers to an alkyl group substituted with a hydroxy group, wherein the alkyl group is as defined above.
[0054] "Halogen" refers to fluorine, chlorine, bromine or iodine, preferably fluorine or iodine.
[0055] An "amino group" refers to -NH2.
[0056] A "cyano group" refers to -CN.
[0057] A "nitro group" refers to --NO.sub.2.
[0058] An "oxo group" refers to =O.
[0059] A "carboxy group" refers to -C(O)OH.
[0060] A "carboxylic acid ester group" refers to a -C(O)O (alkyl) or (cycloalkyl) group, wherein the alkyl and cycloalkyl groups are as defined above.
[0061] "Optional" or "optionally" means that the subsequently described event or circumstance may, but does not necessarily, occur, and the statement includes cases where the event or circumstance occurs and cases where the event or circumstance does not occur. For example, "a heterocycloalkyl group optionally substituted with an alkyl group" means that the alkyl group may, but does not necessarily, be present, and the statement includes cases where the heterocycloalkyl group is substituted with an alkyl group and cases where the heterocycloalkyl group is not substituted with an alkyl group.
[0062] "Substituted" refers to one or more hydrogen atoms of the group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, being replaced independently by the corresponding number of substituents. It goes without saying that the substituents are located only at chemically possible sites, and those skilled in the art can determine possible or impossible substitutions (from experiment or theory) without any special effort. For example, an amino group or a hydroxy group having free hydrogen may be unstable when bonded to a carbon atom having an unsaturated (e.g., olefinic) bond.
[0063] Example 1: Synthesis of Compound 1979 [ka]
[0064] Synthesis of compound 2: Compound 1 (3.0 g, 24.6 mmol) and compound A (5.03 g, 27.0 mmol) were dissolved in THF (80 mL) at room temperature, 3 drops of acetic acid were added, and the mixture was stirred for 30 minutes. Sodium triacetoxyborohydride (15.6 g, 73.8 mmol) was added in several portions, and the mixture was stirred overnight at room temperature after completion. 50 mL of aqueous sodium carbonate was added, and the mixture was extracted twice with ethyl acetate. The organic phases were combined, dried over sodium sulfate, filtered, and concentrated to obtain the crude product of compound 2 (7.8 g).
[0065] Synthesis of compound 4: The crude product of compound 2 (7.8 g, 26.7 mmol) and compound 3 (7.17 g, 22.3 mmol) were dissolved in 1,4-dioxane (150 mL) at room temperature, and Pd2(dba)3 (2.0 g, 2.23 mmol), Xantphos (2.5 g, 4.46 mmol), and potassium carbonate (4.6 g, 33.45 mmol) were added. After nitrogen replacement was performed four times, the mixture was heated and refluxed for 5 hours. After adding 500 mL of water and extracting four times with dichloromethane, the organic phases were combined, dried over sodium sulfate, filtered, and concentrated to obtain the crude product of compound 4, which was further slurried in ethyl acetate (150 mL) for 30 minutes, filtered, and dried to obtain compound 4 (13 g).
[0066] Synthesis of compound 5: Compound 4 (13.0 g, 25 mmol) was dissolved in dichloromethane (50 mL) at room temperature, and 15 mL of trifluoroacetic acid was added and stirred at room temperature overnight. After concentration, the pH was adjusted to 8-9 with saturated sodium carbonate solution, and the mixture was extracted five times with dichloromethane. The organic phases were combined, dried and concentrated, and then subjected to column chromatography with gradient elution using methanol / dichloromethane to obtain compound 5 (6 g), except that the volume ratio of methanol was adjusted to 0-10%.
[0067] 1979 Synthesis: Compound 5 (6 g, 12.5 mmol), bromoethanol (1.9 g, 15.1 mmol) were dissolved in DMF (50 mL) at room temperature, DIPEA (4.9 g, 37.7 mmol) and potassium iodide (catalytic amount) were added, and the mixture was heated to 80 ° C. and reacted for 5 hours. When the end of the reaction was detected by LC-MS, the DMF was concentrated and removed, and the crude product of compound 1979 (3.5 g) was obtained by elution with methanol / dichloromethane in a column chromatography with a gradient of 0-10%, except that the volume ratio of methanol was adjusted to 0-10%, and the mixture was further slurried with 100 mL of ethyl acetate for 30 minutes and filtered to obtain 1979 (3.0 g) (LCMS, M + 1: 523).
[0068] Example 2: Synthesis of Compound 1963 [ka]
[0069] Synthesis of compound 1: Compound A (7.9 g, 39 mmol) and compound B (10 g, 47 mmol) were dissolved in DMF (50 mL) at room temperature, and cesium carbonate (19 g, 58 mmol) was added. The mixture was heated to 120-125°C and reacted for 5 hours. The mixture was cooled to room temperature, 200 mL of water was added, and the mixture was stirred for 30 minutes, filtered, dried, and then slurried in a mixed solvent of ethyl acetate and petroleum ether for 30 minutes, and then filtered to obtain a crude product of compound 1 (8.3 g).
[0070] Synthesis of compound 2: The crude product of compound 1 (8.3 g) was dissolved in methanol (150 mL) at room temperature, Pd / C (1.6 g) was added, and the mixture was purged with hydrogen three times and stirred at room temperature overnight. The crude product was obtained by filtration and concentrating the mother liquor, which was then slurried in a mixed solvent of ethyl acetate and petroleum ether for 30 minutes and filtered to obtain compound 2 (5.3 g).
[0071] Synthesis of compound 4: Compound 2 (5.3 g, 17.2 mmol) and compound 3 (5.1 g, 15.8 mmol) were dissolved in 1,4-dioxane (50 mL) at room temperature, Pd2(dba)3 (0.72 g, 0.8 mmol), Xantphos (0.9 g, 1.7 mmol), and potassium carbonate (3.2 g, 72 mmol) were added, and the mixture was purged with nitrogen four times. The mixture was then heated to reflux for 5 hours, 100 mL of water was added, and the mixture was filtered. The solid was then slurried in ethanol (150 mL) for 30 minutes, filtered, and dried to obtain compound 4 (8.4 g).
[0072] Synthesis of compound 5: Compound 4 (8.4 g, 14.2 mmol) was dissolved in dichloromethane (50 mL) at room temperature, 15 mL of trifluoroacetic acid was added, and the mixture was stirred at room temperature overnight. After concentration, the pH was adjusted to 8-9 with saturated sodium carbonate solution, and the mixture was extracted five times with dichloromethane. The organic phases were combined, dried, concentrated, and then subjected to column chromatography to obtain compound 5 (5 g) by elution with 0-10% methanol / dichloromethane.
[0073] 1963 Synthesis: Compound 5 (3.2 g, 6.5 mmol), bromoethanol (0.9 g, 7.8 mmol) were dissolved in DMF (30 mL) at room temperature, DIPEA (1.72 g, 13.3 mmol) and potassium iodide (catalytic amount) were added, and the mixture was heated to 80 ° C and reacted for 5 hours. When the end of the reaction was detected by LC-MS, the DMF was concentrated and removed, and the mixture was directly subjected to column chromatography to be eluted with 0-10% methanol / dichloromethane to obtain the crude product of compound 1963 (1.6 g), which was further slurried in 100 mL of ethyl acetate for 30 minutes and filtered to obtain 1963 (1.3 g) (LCMS, M + 1: 537).
[0074] Example 3: Synthesis of Compound 1984 [ka]
[0075] Synthesis of compound 2: Compound 1 (18 g, 76 mmol), cesium carbonate (24.6 g, 76 mmol) were added to THF (90 g) at room temperature, the temperature was lowered to 0-5 ° C, the temperature was controlled to less than 10 ° C, isopropylamine (4.5 g, 76 mmol) was added dropwise, and when it was completed, it was reacted at room temperature for 5 hours, and when the end of the reaction was detected by LC-MS, it was filtered and concentrated to obtain 22 g of a reddish brown solid. The reddish brown solid (22 g, 79 mmol) was added to a mixed solution of ethanol (80 mL) and water (20 mL), ammonium chloride (7.94 g, 148 mmol), and iron powder (25.3 g, 454 mmol) were added, and the temperature was raised to reflux and reacted for 1 hour, and when the end of the reaction was detected by LC-MS, water and EA were added, stirred, filtered, the aqueous phase was extracted with EA, dried and concentrated, and subjected to column chromatography to elute with PE to obtain compound 2 (brown liquid 12.1 g).
[0076] Synthesis of compound 3: Compound 2 (3 g, 12.14 mmol) was added to a mixture of water (12 mL) and concentrated hydrochloric acid (6 mL), hydroxyacetic acid (4.6 g, 60.7 mmol) was added, and the mixture was heated to reflux and reacted for 3 hours. When the completion of the reaction was detected by LC-MS, the temperature was lowered and the pH was adjusted to about 8-9 with sodium carbonate solution. The mixture was extracted with EA, dried and concentrated to obtain a yellow solid compound 3 (3.1 g).
[0077] Synthesis of compound 4: Compound 3 (3g, 10.44mmol) was added to DCM (30mL), the temperature was lowered to 0-5℃, and Dast reagent (2.02g, 12.54mmol) was added dropwise at less than 10℃. The reaction was carried out at room temperature, and then the reaction was carried out under reflux. Dast reagent (0.6g) was added, and the reaction was continued under reflux for 24 hours. When most of the raw materials were converted by LC-MS, the temperature was lowered, the pH was adjusted to 8 with sodium bicarbonate, and the mixture was extracted with DCM and subjected to column chromatography to obtain yellow solid compound 4 (0.9g) by elution with 0-5% EA.
[0078] One-pot synthesis of compounds 5 and 6: Compound 4 (0.92 g, 3.2 mmol), bis(pinacolato)diboron (0.96 g, 3.8 mmol), potassium acetate (0.62 g, 6.36 mmol), and Pd(dppf)Cl2 (0.22 g, 0.64 mmol) were added in this order to dioxane (30 mL), and the reaction was carried out under reflux for 2 hours under the protection of nitrogen. When the completion of the reaction was detected by LC-MS, the temperature was lowered and sodium carbonate (0.67 g, 6.36 mmol), chlorine, and ethyl acetate were added. Compound B (0.53 g, 3.2 mmol) was added to the reaction system of compound 5, Pd(dppf)Cl2 (0.11 g, 0.32 mmol) and water (7 mL) were added, and the temperature was raised to 80-90 °C under the protection of nitrogen for 2 hours. When the completion of the reaction was detected by LC-MS, the temperature was lowered and water was added, extracted with EA, dried and concentrated, and subjected to column chromatography eluting with 0-15% EA to obtain yellow solid compound 6 (0.62 g).
[0079] Synthesis of compound 1984: Compound 6 (0.15 g, 0.44 mmol) and compound 7 (0.11 g, 0.484 mmol) were added to dioxane, Pd2(dba)3 (44.4 mg, 0.044 mmol), Xantphos (51 mg, 0.088 mmol), and potassium carbonate (91.2 mg, 0.66 mmol) were added, and the reaction was carried out under reflux under nitrogen protection at an increased temperature. When the completion of the reaction was detected by LC-MS, the temperature was lowered, water was added, and the mixture was extracted with DCM. Yellow solid compound 1984 (98 mg) was scraped off from the plate (LCMS, M+1:525).
[0080] Example 4: Other Preparations Other compound preparation examples are as follows. [ka] [ka] [ka]
[0081] Example 5: Measurement of CDK2 kinase activity In vitro CDK2 kinase activity was tested by the following method. Final reaction buffer: 100mM 4-hydroxyethylpiperazineethanesulfonic acid, pH 7.5, 0.1% bovine serum albumin, 0.01% Triton X-100, 1mM dithiothreitol, 5mM magnesium chloride, 10 μM sodium orthovanadate, 10 μM sodium β-glycerophosphate, 10 μM ATP, 1% DMSO (from test compound), Substrate peptide: 1 μM FAM-PKTPKKAKKL-OH, FAM is 5-carboxyfluorescein, 0.1nM CDK2 / human cyclin E .
[0082] 5 μL of buffer was added to a 384-well plate, 0.1 μL of test compound (DMSO, 100 times the highest concentration), and 5 μL of substrate peptide buffer were added. The reaction was stopped with EDTA after incubation at 25° C. for 6 hours. The electrophoretic analysis device was started (Caliper LabChip® 3000 Drug Discovery System, blue laser (480 nm) excitation, green CCD (520 nm) CCD2 detection). Details of the inhibitory effect of the test compound on CDK2 kinase activity are shown in Table 1.
[0083] Example 6: Measurement of CDK4 kinase activity In vitro CDK4 kinase activity was tested as follows. Final reaction buffer: 100 mM 4-hydroxyethylpiperazineethanesulfonic acid, pH 7.5, 0.1% bovine serum albumin, 0.01% Triton X-100, 1mM dithiothreitol, 5mM magnesium chloride, 10 μM sodium orthovanadate, 10 μM sodium β-glycerophosphate, 25 μM ATP, 1% DMSO (from test compound), Substrate peptide: 1 μM FAM-RRFRPASPLRGPPK-NH2 fragment, FAM is 5-carboxyfluorescein, 5nM CDK4 / human cyclin D 1 .
[0084] 5 μL of buffer was added to a 384-well plate, 0.1 μL of test compound (DMSO, 100 times the highest concentration), and 5 μL of substrate peptide buffer were added. The reaction was stopped with EDTA after incubation at 25° C. for 6 hours. The electrophoretic analysis device was started (Caliper LabChip® 3000 Drug Discovery System, blue laser (480 nm) excitation, green CCD (520 nm) CCD2 detection). Details of the inhibitory effect of the test compound on CDK4 kinase activity are shown in Table 1.
[0085] Example 7: Measurement of CDK6 kinase activity In vitro CDK6 kinase activity was tested as follows. 2nM CDK6 / human cyclin D3 (Carna, Catalog No. 04-107) Final reaction buffer: 100mM 4-hydroxyethylpiperazineethanesulfonic acid, pH 7.5, 0.1% bovine serum albumin, 0.01% Triton X-100, 1mM dithiothreitol, 5mM magnesium chloride, 10 μM sodium orthovanadate, 10 μM sodium β-glycerophosphate, 300 μM ATP, 1% DMSO (from test compound), Substrate peptide: Dyrktide, 5 μL of buffer was added to a 384-well plate, 0.1 μL of test compound (DMSO, 100 times the highest concentration), and 5 μL of substrate peptide buffer were added. The reaction was stopped with EDTA after incubation at 25° C. for 3 hours. The electrophoretic analysis device was started (Caliper LabChip® 3000 Drug Discovery System, blue laser (480 nm) excitation, green CCD (520 nm) CCD2 detection). Details of the inhibitory effect of the test compound on CDK6 kinase activity are shown in Table 1.
[0086] Example 8: Measurement of MDA-MB-468 cell activity MDA-MB-468 (ATCC, Catalog No. HTB-132); RPMI 1640 (Invitrogen, Catalog No. 22400089), FBS (Hyclone, catalog number SV30087.03), Pen Strep (Hyclone, catalog number SV30010), CellTiter-Glo (Promega, Catalog No. G7573), Culture medium: 89% RPMI 1640, 10% FBS, 1% Pen Strep. 300 MDA-MB-468 cells and 50μL of medium were added to the plate, 100μL of PBS buffer was added, and the cells were incubated under 37℃ / 5%CO2 for 24 hours. Samples of the test compounds were taken at 10 test points, and the samples were diluted with DMSO in quadruplicate, 250nL was added to the plate, and the cells were incubated under 37℃ / 5%CO2 for 5 days. 25μL of CellTiter-Glo was added to each plate, and the cells were rotated for 15 seconds, centrifuged (1000rpm), shaken and mixed for 10 minutes (400rpm), and the microplate reader Envision was started to read the results. The detailed results of the inhibitory effect of the test compounds on MDA-MB-468 cell activity are shown in Table 1. [Table 1] IC of example compounds for CDK2 kinase activity, CDK4 kinase activity, CDK6 kinase activity and MDA-MB-468 cell activity 50 data [Table 1] *:Invest New Drugs(2014)32,825-837. **: What was measured with Abemaciclib is that it inhibits the activity of CDK6 / CycD1.
[0087] As can be seen from the above, the pyrimidine derivatives of the present invention exhibit excellent CDK inhibitory effects and functions, particularly inhibiting CDK2, CDK4, and CDK6. 50 Also, when X contains a methoxy group, a hydroxy group, or an imino group, it has a very excellent effect.
[0088] It should be noted that the above examples are for illustrating the technical solutions of the present application, and are not intended to be limiting. Although the present application is described in detail with reference to the above examples, those skilled in the art can still make modifications to the technical solutions described in the above examples, or equivalent replacements for some technical features thereof, and these modifications or replacements do not deviate from the spirit and scope of the corresponding technical solutions of the present application. [Industrial Applicability]
[0089] The pyrimidine derivatives of the present application exhibit excellent CDK inhibitory effects and functions, particularly inhibiting CDK2, CDK4, and CDK6. They have a lower IC 50 Therefore, it can be used as an active ingredient in the treatment of various diseases (e.g., cell proliferation disorders, infectious diseases, inflammatory diseases, autoimmune diseases, cardiovascular diseases or neurodegenerative diseases, blood toxicity diseases caused by radiation, etc.).
Claims
1. A pyrimidine derivative selected from compounds having the following structure: [Case 1A] [chemical 1B] [Case 1C]
2. (1) Cyclization of existing compounds I-A and I-B to generate benzimidazole I-C, which is then converted to a boronic acid pinacol ester, which is then reacted with I-D via Suzuki coupling to generate I-E, and finally, reaction of I-E with the corresponding 2-aminopyridine via Buchwald-Hartwig coupling to generate the compound of formula I; [Case 2] (2) [C3] (3) [C4] A method selected from one or more of the following: In the formula, R 1 , R 2 , R 3 2. The method for producing a pyrimidine derivative according to claim 1, wherein A, Q and X are the same as the corresponding groups in the pyrimidine derivative according to claim 1, and Y is a halogen atom.
3. Use of the pyrimidine derivative according to claim 1 as an active ingredient in the manufacture of a pharmaceutical composition for treating a cell proliferation disorder, an infectious disease, an inflammatory disease, an autoimmune disease, a cardiovascular disease, a neurodegenerative disease, or a blood toxicity disease caused by radiation.
4. 4. The use according to claim 3, characterized in that the infection is selected from a viral infection or a fungal infection.
5. 5. The use according to claim 4, characterized in that the viral infection is selected from herpes or HIV infection.
6. 4. The use according to claim 3, characterized in that the inflammatory disease is selected from rheumatoid arthritis or osteoarthritis.
7. 4. The use according to claim 3, characterized in that the autoimmune disease is selected from psoriasis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis or glomerulonephritis.
8. 4. The use according to claim 3, characterized in that the cardiovascular disease is selected from myocardial infarction, stroke, atherosclerosis, postoperative vascular stenosis or restenosis.
9. 4. The use according to claim 3, wherein the neurodegenerative disease is selected from Alzheimer's disease or Parkinson's disease.
10. 4. The use according to claim 3, wherein the radiation-induced hematotoxicity disease is selected from bone marrow suppression, neutropenia, leukopenia, or anemia.
11. The use according to claim 3, wherein the treating the cell proliferation disorder is treating cancer.
12. The use according to claim 11, characterized in that the cancer is selected from breast cancer, ovarian cancer, prostate cancer, melanoma, brain tumor, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer, lung cancer, renal cancer, skin cancer, glioblastoma, neuroblastoma, sarcoma, liposarcoma, osteochondroma, osteoma, osteosarcoma, seminoma, testicular tumor, uterine cancer, head and neck tumor, multiple myeloma, malignant lymphoma, polycythemia vera, leukemia, thyroid tumor, ureter tumor, bladder tumor, gallbladder cancer, bile duct cancer, choriocarcinoma, or childhood cancer.
13. the brain tumor is a glioma with malignant astrocytoma and oligodendroglioma components; The colorectal cancer is selected from colon cancer or rectal cancer; The lung cancer is selected from non-small cell lung cancer, small cell lung cancer, primary or metastatic squamous cell carcinoma; The uterine cancer is selected from cervical cancer or endometrial cancer; The head and neck tumor is selected from maxillary cancer, laryngeal cancer, pharyngeal cancer, tongue cancer, or oral cancer; The malignant lymphoma is selected from reticulum cell sarcoma, lymphosarcoma, Hodgkin's lymphoma, or mantle cell lymphoma; The leukemia is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia; The childhood cancer is selected from Ewing's sarcoma family of tumors, Wilms' tumor, rhabdomyosarcoma, hemangiosarcoma, embryonal testicular tumor, neuroblastoma, retinoblastoma, hepatoblastoma, or nephroblastoma.
13. The use according to claim 12.
14. The use according to claim 12, characterized in that the cancer is selected from breast cancer or ovarian cancer.
15. The use according to claim 14, wherein the breast cancer is triple-negative breast cancer.
16. A pharmaceutical composition comprising the pyrimidine derivative according to claim 1 as an active ingredient, and further comprising one or more pharma- ceutically acceptable carriers, diluents or excipients.
17. A CDK inhibitor comprising the pyrimidine derivative according to claim 1.
18. The CDK inhibitor according to claim 17, characterized in that the CDK comprises CDK2, CDK4 or CDK6.
19. A method for producing the CDK inhibitor according to claim 17 or 18, comprising the step of producing the pyrimidine derivative according to claim 1 using the production method according to claim 2.
20. Use of the CDK inhibitor according to claim 17 or 18 in the manufacture of a pharmaceutical composition comprising the CDK inhibitor according to claim 17 or 18 as an active ingredient for treating a cell proliferation disorder, an infectious disease, an inflammatory disease, an autoimmune disease, a cardiovascular disease, a neurodegenerative disease, or a blood toxicity disease caused by radiation.
21. 21. The use according to claim 20, characterized in that the infection is selected from a viral infection or a fungal infection.
22. 22. The use according to claim 21, characterized in that the viral infection is selected from herpes or HIV.
23. 21. The use according to claim 20, characterized in that the inflammatory disease is selected from rheumatoid arthritis or osteoarthritis.
24. 21. The use according to claim 20, characterized in that the autoimmune disease is selected from psoriasis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis or glomerulonephritis.
25. 21. The use according to claim 20, characterized in that the cardiovascular disease is selected from myocardial infarction, stroke, atherosclerosis, postoperative vascular stenosis or restenosis.
26. 21. The use according to claim 20, wherein the neurodegenerative disease is selected from Alzheimer's disease or Parkinson's disease.
27. The use according to claim 20, characterized in that the radiation-induced hematotoxic disease is selected from bone marrow suppression, neutropenia, leukopenia or anemia.
28. The use according to claim 20, wherein the treating the cell proliferative disorder is treating cancer.
29. 29. The use according to claim 28, characterized in that the cancer is selected from breast cancer, ovarian cancer, prostate cancer, melanoma, brain tumor, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer, lung cancer, renal cancer, skin cancer, glioblastoma, neuroblastoma, sarcoma, liposarcoma, osteochondroma, osteoma, osteosarcoma, seminoma, testicular tumor, uterine cancer, head and neck tumor, multiple myeloma, malignant lymphoma, polycythemia vera, leukemia, thyroid tumor, ureter tumor, bladder tumor, gallbladder cancer, bile duct cancer, choriocarcinoma, or childhood cancer.
30. the brain tumor is a glioma with malignant astrocytoma and oligodendroglioma components; The colorectal cancer is selected from colon cancer or rectal cancer; The lung cancer is selected from non-small cell lung cancer, small cell lung cancer, primary or metastatic squamous cell carcinoma; The uterine cancer is selected from cervical cancer or endometrial cancer; The head and neck tumor is selected from maxillary cancer, laryngeal cancer, pharyngeal cancer, tongue cancer, or oral cancer; The malignant lymphoma is selected from reticulum cell sarcoma, lymphosarcoma, Hodgkin's lymphoma, or mantle cell lymphoma; The leukemia is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia; The childhood cancer is selected from Ewing's sarcoma family of tumors, Wilms' tumor, rhabdomyosarcoma, hemangiosarcoma, embryonal testicular tumor, neuroblastoma, retinoblastoma, hepatoblastoma, or nephroblastoma.
30. The use according to claim 29.
31. 30. The use according to claim 29, wherein the cancer is selected from breast cancer or ovarian cancer.
32. 32. The use of claim 31 , wherein the breast cancer is triple-negative breast cancer.
33. 19. A pharmaceutical composition comprising as an active ingredient a CDK inhibitor according to claim 17 or 18, and further comprising one or more pharma- ceutically acceptable carriers, diluents or excipients.
Citation Information
Patent Citations
Protein kinase inhibitors
JP2012513396A
Combination therapy of a Notch inhibitor and a CDK4 / 6 inhibitor for the treatment of cancer
JP2019511526A
Compounds as CDK small-molecule inhibitors and uses thereof
WO2016015605A1
